EMA Refused: Cabazitaxel Teva (cabazitaxel) — Teva B.V.

View source ↗

Summary

The EMA refused the cabazitaxel product Teva B.V. for therapeutic use in prostatic neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostatic Neoplasms

Drugs mentioned

• Cabazitaxel Teva (cabazitaxel)

Snippet

Status: Refused. Therapeutic area: Prostatic Neoplasms. MAH: Teva B.V.. Decision date: 26/04/2019